Amgen Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Amgen Inc. (AMGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.30% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-12.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2020-02-12
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was 0.30%, a 50.00% increase from fiscal 2018.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was 0.20%, a 71.43% decline from fiscal 2017.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was 0.70%, a 46.15% decline from fiscal 2016.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was 1.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2019-12-31 | 0.30% 10-K · filed 2020-02-12 |
| 2018-12-31 | 0.20% 10-K · filed 2020-02-12 |
| 2017-12-31 | 0.70% 10-K · filed 2020-02-12 |
| 2016-12-31 | 1.30% 10-K · filed 2019-02-13 |
| 2015-12-31 | 0.00% 10-K · filed 2018-02-13 |
| 2014-12-31 | 0.00% 10-K · filed 2017-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |